NCT06873854

A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours

Evaluation of a Phase II, Single-arm, Multicenter, Open-label Clinical Study on LM-108 Injection in Combination With Toripalimab for Advanced Malignant Solid Tumors in Patients With Unresectable or Metastatic Microsatellite Highly Unstable (MSI H) or Mismatch Repair Defects (dMMR) Who Have Failed Previous Treatment With Anti-PD-1/PD-L1 Drugs

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 84 (estimated)
• Sponsor: LaNova Medicines Limited · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Based on overall response rate (ORR) as assessed by the Independent Review Committee (IRC) against the Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria for Solid Tumor Efficacy, To evaluate the efficacy of LM-108 in combination with Toripalimab in patients with advanced malignant solid tumours with unresectable or metastatic MSI-H/dMMR who have failed previous anti-PD-1 /PD-L1 therapy.

Conditions

• Advanced Solid Tumor

Interventions

Type	Name	Description
DRUG	LM-108	Q3W, Intravenous Drip
DRUG	Toripalimab	Q3W, Intravenous Drip

Timeline

• Start date: 2025-03-26
• Primary completion: 2028-01-26
• Completion: 2030-01-26
• First posted: 2025-03-13
• Last updated: 2025-03-13

Locations

1 site across 1 country: China